2015 Volume 27 Issue 3 Pages 47-52
The incidence of intracranial hemorrhage during treatment with novel non-vitamin K antagonist oral anticoagulants; (NOACs) such as-dabigatran, rivaroxaban, and apixaban is lower than that during warfarin treatment. The characteristics of intracranial hemorrhage during NOACs therapy, however, remain unclear. Hematomas that arise owing to acute intracranial hemorrhage during NOACs treatment have been reported as small in size. However, we present two cases suggestives of hematoma expansion during NOACs treatment. The propriety and timing of resumption of anticoagulation after anticoagulation-related intracranial hemorrhage remains uncertain. In this article, we review the clinical and, radiological characteristics of NOACs-related intracranial hemorrhage.
